Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company
("Provectus"), announced today that it has agreed to sponsor the
activities of the American Association of Physicians of Indian Origin
(AAPI). In addition, Provectus will participate at AAPI's 2015 Global
Healthcare Summit in Mumbai, India, running from January 2-4, 2015, as
well as at the Annual AAPI Conference in Orlando, Florida, running from
June 17-21, 2015.
Peter Culpepper, COO and CFO of Provectus, said, “We are very pleased to
be sponsoring AAPI in the coming year, and we believe the relationship
will benefit both AAPI and our shareholders. One of the benefits to
Provectus will be engaging the Indian market through trusted physicians
for PV-10, our novel investigational cancer treatment. We expect this
will not only assist us in gaining regulatory approval in India but also
will support our patient recruitment efforts as we embark on our phase 3
clinical trial of PV-10 for the treatment of melanoma.”
He continued, “AAPI is the umbrella organization representing the
interests of over 60,000 doctors of Indian origin in the USA, and there
are over 25,000 medical residents and fellows currently in USA. This
gives us tremendous reach in America as well as on the subcontinent. One
in every seven American patients is seen by an Indian doctor, and this
ratio is even higher in the smaller towns and underserved areas due to
the larger proportion of Indian doctors in more remote locations. As a
result, the Indian doctor also serves the most diverse group of patients
in the USA including Caucasians, African Americans, Hispanics and other
groups, which is important for clinical research and trials.”
Mr. Culpepper concluded, “We will hit the ground running with AAPI by
attending their Global Healthcare Summit (GHS) in Mumbai, India,
starting January 2, 2015. At this GHS, we expect around 800 delegates to
attend. Between 150 and 200 will be from the USA, and some from the
United Kingdom, Canada, Middle East and Australia. In addition, AAPI
will have a live extension to its members in the USA who are unable to
attend, as well a live telecast to an estimated 50,000 doctors around
India. We will inform this huge group of doctors from around the globe
about the progress we have made with PV-10 to date, what we are planning
in the anticipated phase 3 clinical trial, and what we have learned
about PV-10 for indications other than melanoma.”
Dr. Ravi Jahagirdar, MD, President of AAPI, said, “We are very happy to
have Provectus as an official sponsor of AAPI and to enjoy their
participation at our coming meetings in Mumbai and Orlando in 2015. The
Indian diaspora offers a unique, global network of physicians who can
increase the communication of medical developments like the clinical
results shown thus far for PV-10. Moreover, we have close professional,
educational and family ties to India itself, a nation of 1 billion. We
believe this introduction of Provectus to the healthcare industry in
India will be well received, since PV-10 has many features that make it
well suited for local conditions.”
Provectus has also expanded the membership of its Strategic Advisory
Board with the addition of Deanna Angello, Director, Commercial Strategy
and New Business Planning for the Global Established Pharma business at
Pfizer Inc. In this role, she is focused on new business opportunities
for the US region, notably in areas such as licensing of new assets,
mergers and acquisitions, and strategic partnerships. She was promoted
to this position from her role as Senior Manager, Marketing, Lyrica, a
product approved for fibomyalgia, diabetic peripheral neuropathy and
other pain-related conditions. Prior to that she was in Strategy &
Analytics, where she worked on diabetes and Alzheimer’s disease
products. Before joining Pfizer, Deanna was a management consultant at
Booz Allen and Bearing Point where her efforts concentrated on strategic
planning, organizational effectiveness and business process improvement.
Ms. Angello holds a B.S. in Psychology from the University of Pittsburgh
and a Masters in Business Administration from the Kelley School of
Business at Indiana University. As part of her graduate studies, she
studied for a semester at St. Gallen University in Switzerland. Ms.
Angello also serves as a Board Member of the Association for
Frontotemporal Degeneration (AFTD), a national and dynamic 501(c)(3)
healthcare non-profit dedicated to raising awareness and ultimately
finding a cure for frontotemproal degeneration (FTD), a rare
neurodegenerative disease.
Dr. Craig Dees, Ph.D., CEO of Provectus, said, “We are delighted to have
Deanna join our Strategic Advisory Board. She is a highly experienced,
forward-thinking healthcare and pharmaceutical strategist, with
commercial experience in marketing and business development and we look
forward to working with her in the coming months.”
Ms. Angello stated, “I am very pleased to be joining the Provectus
Strategic Advisory Board just as they are beginning their phase 3
clinical trial of Intralesional PV-10 for the treatment of melanoma. It
is a very exciting time for the Company both scientifically and
commercially, and I look forward to contributing to its success.”
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing oncology
and dermatology therapies. PV-10, its novel investigational drug for
cancer, is designed for injection into solid tumors (intralesional
administration), thereby reducing potential for systemic side effects.
Its oncology focus is on melanoma, breast cancer and cancers of the
liver. The Company has received orphan drug designations from the FDA
for its melanoma and hepatocellular carcinoma indications. PH-10, its
topical investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has completed
phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of
PH-10 as a topical treatment for atopic dermatitis and psoriasis.
Information about these and the Company’s other clinical trials can be
found at the NIH registry, www.clinicaltrials.gov.
For additional information about Provectus, please visit the Company’s
website at www.pvct.com
or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking
statements" as defined under U.S. federal securities laws. These
statements reflect management’s current knowledge, assumptions, beliefs,
estimates, and expectations and express management’s current views of
future performance, results, and trends and may be identified by their
use of terms such as "anticipate," "believe," "could," "estimate,"
"expect," "intend," "may," "plan," "predict," "project," "will," and
other similar terms. Forward-looking statements are subject to a number
of risks and uncertainties that could cause our actual results to
materially differ from those described in the forward-looking
statements. Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking statements
include those discussed in our filings with the Securities and Exchange
Commission (including those described in Item 1A of our Annual Report on
Form 10-K for the year ended December 31, 2013, and in our Quarterly
Reports on Form 10-Q for the quarters ended March 31, 2014, June 30,
2014, and September 30, 2014), and the following:
our determination, based on guidance from the FDA, whether to proceed
with or without a partner with a phase 3 trial of PV-10 to treat locally
advanced cutaneous melanoma and the costs associated with such a trial
if it is necessary;
our determination whether to license PV-10, our melanoma drug product
candidate, and other solid tumors such as liver cancer, if such
licensure is appropriate considering the timing and structure of such a
license, or to commercialize PV-10 on our own to treat melanoma and
other solid tumors such as liver cancer;
our ability to license our dermatology drug product candidate, PH-10, on
the basis of our phase 2 atopic dermatitis and psoriasis results, which
are in the process of being further developed in conjunction with
mechanism of action studies; and
our ability to raise additional capital if we determine to commercialize
PV-10 and/or PH-10 on our own, although our expectation is to be
acquired by a prospective pharmaceutical or biotech concern prior to
commercialization.
Copyright Business Wire 2014